{"entity":{"id":"altay-therapeutics","kind":"company","name":"Altay Therapeutics","aka":[],"tldr":"Altay Therapeutics is developing small-molecule drugs for chronic liver disease, including the scarring that leads to liver cancer and liver cancer itself.","summary":"Altay Therapeutics develops oral small molecules against transcription-factor-driven pathways in liver fibrosis and hepatocellular carcinoma. Its YC profile reports preclinical mouse data showing reduction and partial reversal of fibrosis, and a plan to reach phase 1. The co-founder led early development of pirfenidone, the first approved drug for lung fibrosis. Oncology is one of two stated indications; programmes are preclinical as far as public sources show. Included because liver cancer is an explicit target.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/altay-therapeutics"},{"label":"Official website","url":"https://www.altaytherapeutics.com"}],"tags":["yc"],"related":[],"cancers":["hcc"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.altaytherapeutics.com","stage":"startup","ycBatch":"W20","investors":["y-combinator"],"funding":[]},"route":"/companies/altay-therapeutics/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"company":[{"id":"y-combinator","kind":"company","name":"Y Combinator","route":"/companies/y-combinator/"}]}}